Sanofi reaffirmed earnings guidance for the year 2024. The company expects 2024 business EPS to remain roughly stable excluding the impact of an expected effective tax rate increase to 21% and decrease low single-digit at CER including the higher expected tax rate, barring unforeseen major adverse events.